GE Healthcare has collaborated with biotechnology company Indi Molecular to develop a diagnostic tool for the clinical management of patients receiving immunotherapy, a type of cancer treatment.
The alliance will use Indi Molecular’s Protein Catalyzed Capture (PCC) technology to create immune cell-targeted positron-emission tomography (PET) tracer candidates.
These PET trace candidates are expected to allow identification of molecular markers of cytotoxic T-cells, along with selection and monitoring of immunotherapy patients.
According to GE Healthcare, the tracers could help gain better insights into the patient’s immune cell profile and offer an early indication of therapy response. This will improve clinical trial outcomes via better chances of immunotherapies reaching the market.
Indi Molecular CEO and co-founder Albert Luderer said: “We believe that our protein-catalysed capture technology platform is ideally suited to deliver predictable, small molecule-like biological behaviour that possesses unique, ultra-high target affinity and specificity required for targets such as immune cells.”
GE Healthcare is focused on medtech and diagnostics for precision health. It is developing a portfolio of PET tracers targeting immunotherapy biomarkers within precision diagnostics.
The company’s PET tracers are being used in drug clinical trials worldwide.
GE Healthcare Molecular Imaging general manager Julia Casey said: “With Indi Molecular as one of our collaborators, we can now begin to develop novel PET tracers for a variety of biomarkers of interest in the immuno-oncology space.
“These tracers could potentially play a critical role in supporting the development of immunotherapies, treatments that have shown great promise in how we manage oncology patients today.”
The healthcare business of GE offers medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies. Its portfolio includes precision diagnostics, therapeutics and monitoring devices, data analytics, applications and services.